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Oxidized low-density lipoproteins (oxLDL) play a pivotal role in the etiopathogenesis of atherosclerosis through the activation of
inflammatory signaling events eventually leading to endothelial dysfunction and senescence. In the present work, we investigated
the effects of indicaxanthin, a bioavailable, redox-modulating phytochemical from Opuntia ficus indica fruits, with
anti-inflammatory activity, against oxLDL-induced endothelial dysfunction. Human umbilical vein cord cells (HUVEC) were
stimulated with human oxLDL, and the effects of indicaxanthin were evaluated in a range between 5 and 20 μM, consistent with
its plasma level after a fruit meal (7 μM). Pretreatment with indicaxanthin significantly and concentration-dependently
inhibited oxLDL-induced cytotoxicity; ICAM-1, VCAM-1, and ELAM-1 increase; and ABC-A1 decrease of both protein and
mRNA levels. From a mechanistic perspective, we also provided evidence that the protective effects of indicaxanthin were
redox-dependent and related to the pigment efficacy to inhibit NF-κB transcriptional activity. In conclusion, here we
demonstrate indicaxanthin as a novel, dietary phytochemical, able to exert significant protective vascular effects in vitro, at
nutritionally relevant concentrations.
1. Introduction
Atherosclerosis is a long, multifactorial, inflammatory pro-
cess characterized by the accumulation of lipids in the wall
of large- and medium-sized arteries [1, 2]. According to the
oxidative theory of atherosclerosis, and its modifications over
the last decade, hypercholesterolemia is one of the major risk
factors of this condition as it triggers the accumulation of oxi-
dized low-density lipoproteins (oxLDL) in the subintimal
space [1, 2]. In areas at risk of atherosclerosis (e.g., at arterial
bifurcations), the turbulent blood flow induces an endothelial
activation, characterized by a local inflammatory response
that generates an endocellular oxidative and nitrosative stress
[3]. The increased levels of reactive oxygen and nitrogen
species (RONS) activates selected redox-dependent tran-
scription factors, such as NF-κB, that in turn induce an
overexpression of endothelial adhesion molecules such as
ICAM-1, VCAM-1, and ELAM-1 [1, 2]. This phenomenon
increases the adhesion of leukocytes that eventually transmi-
grate in the subendothelial space where they are converted in
macrophages. At the same time, the enhanced endothelial
permeability favors the influx of LDL into the subendothelial
intima where the inflammatory cells generate RONS induc-
ing a progressive LDL oxidation. oxLDL, then, interact with
endothelial cells (EC), disrupt the antioxidant defences of
vascular endothelium, and boost leukocyte chemotaxis,
reinforcing the whole inflammatory reaction that leads to a
persistent EC dysfunction. As a consequence, a chronic sys-
temic inflammatory response is established and eventually
results in the proliferation of macrophagic foam cells and
the formation of fatty streaks, the hallmark of the early ath-
erosclerotic lesions [3].
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In line with the key role of LDL in atherosclerosis,
ATP-binding cassette A1 (ABC-A1), the cholesterol efflux
system present in all tissues, endothelium included, has
been demonstrated to offer antiatherogenic protection [4, 5].
Indeed, under physiological conditions, synthesized choles-
terol can efflux fromEC through ABC-A1 tomaintain choles-
terol homeostasis. Disturbed flow and oxLDL inhibit
ABC-A1-mediated cholesterol efflux. As a result, cholesterol
is removed through other pathways which may lead to lipid
deposition in the subendothelial space [4–6].
Notwithstanding the solid basis of the oxidative theory
of atherosclerosis, the vast majority of clinical trials and
all meta-analyses surprisingly conclude that antioxidant
vitamin supplementation has no beneficial effect on cardio-
vascular events. On the other hand, the association between
“Mediterranean diet” and reduction of major chronic
degenerative diseases, including the cardiovascular ones,
appears robust and conclusive [1, 7, 8], suggesting the
involvement of other redox-dependent molecular controls.
In comparison to other fruits within the “Mediterranean
diet” (e.g., oranges, lemons, and grapes), cactus pear
(Opuntia ficus indica, L Mill) fruit is one that is less con-
sumed and less studied, notwithstanding its abundance
throughout selected areas of Italy, Spain, Greece, and North
African countries.
Indicaxanthin (Figure 1), a betalain pigment from cactus
pear fruit, has been theobject of soundexperimentalworkover
the last years [9]. As with many phytochemicals, it is a
redox-active compound and has been shown to act as antiox-
idant in a number of in vitro studies [9]. Interestingly, thanks
to its charged portions, ionizable groups, and lipophilic
moieties, it is amphiphilic [10] and has been demonstrated
to interact with cell membranes [11]. This feature is critical
to allowbioactive compounds to interactwith cells and initiate
signaling events. In this regard, indicaxanthin has been shown
to modulate specific redox-dependent signaling pathways
involved in macrophage activation and apoptosis and
epithelial and endothelial dysfunction in vitro [9, 12, 13].
Remarkably, and in contrast with the majority of dietary phy-
tochemicals, indicaxanthin is highly bioavailable [14]. The
molecule has been shown to cross the unaltered intestinal epi-
thelial cell in vitro being absorbed through paracellular junc-
tions [11]. In line with that, indicaxanthin has been found in
human plasma at a 7 μM peak concentration 3h after the
ingestionof four cactus pear fruits containing 28mgof thepig-
ment [14]. Moreover, its amphiphilicity allows it to cross the
blood-brain barrier, located within the CNS, and modulate
its bioelectric activity [15]. Finally, thanks to its bioavailability
and redox-modulatingproperties, indicaxanthin exerts signif-
icant pharmacological effects in vivo. Indeed, oral administra-
tion of the phytochemical at nutritionally relevant doses
(2 μmol/kg) generates, in rats, a plasma peak concentration
of 0.2 μM able to exert strong anti-inflammatory effects in a
model of acute inflammation [16].
In the light of the strong interconnections between inflam-
mation, atherosclerosis, and diet, and the anti-inflammatory
and redox-modulating properties of indicaxanthin, the aim
of this work was to evaluate the effects of the phytochemical,
at nutritionally relevant concentrations, in an in vitro model
of innate immunity activation represented by oxLDL-
induced endothelial dysfunction. To this end, we investigated
whether indicaxanthin prevented the oxLDL-mediated
adhesion molecule overexpression and ABC-A1 downregu-
lation, in human cultured EC. Mechanistic details of the
redox-dependent NF-κB transcriptional activity have also
been investigated.
2. Materials and Methods
2.1. Reagents. All reagents, unless otherwise stated, were from
Sigma-Aldrich (Milan, Italy) and of the highest available
purity grade.
2.2. Extraction and Purification of Indicaxanthin from Cactus
Pear Fruits. Indicaxanthin was isolated from cactus pear
(Opuntia ficus indica) fruits (yellow cultivar) as previously
described [16].
2.3. Isolation and Oxidation of Human LDL. Blood samples
from healthy subjects with informed consent were obtained
after an overnight fasting. LDL were isolated from plasma
as previously described [17] and diluted to 100μg protein/ml
in PBS. Protein concentration of the particle was evaluated by
Bradford assay as reported elsewhere [17].
Aliquots of native LDL (nLDL) were then subjected to
lipid oxidation by treatment with 5μM CuSO4 at 37
°C for
24 h, as previously described [14].
The oxidation state of LDL, in terms of conjugated dienes
(CD) hydroperoxides and thiobarbituric acid-reactive sub-
stances (TBARS), was evaluated as previously reported [14].
oxLDL were then concentrated with centrifugal filter
devices according to the manufacturer’s instructions (Milli-
pore, Milan, Italy) to a value of 100μg protein/ml. All sam-
ples (nLDL and oxLDL) were filter-sterilized (0.2μm
Millipore filters, Milan, Italy), aliquoted, and stored at
-80°C up to one month.
2.4. Cell Culture. HUVEC (human umbilical vein endothelial
cells) were purchased from Lonza (Milan, Italy), grown in
endothelial growth medium (Lonza) at 37°C in a humidified
incubator under 5% CO2, subcultured by trypsinization, and
used up to passage 4.
2.5. HUVEC Treatment. In order to perform the experiments,
cells were seeded in 6-well plates at a density of 2× 104 cells/-
well. Upon 80% confluence, HUVEC were incubated, after
overnight starving, either in the absence (control cells) or in
the presence of 100μg oxLDL/ml for 16 h in a serum-free
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Figure 1: Chemical structure of indicaxanthin.
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endothelial basal medium (Lonza, Milan, Italy). When neces-
sary, HUVEC were pretreated for 1 h with indicaxanthin and
then stimulated with oxLDL as described above.
2.6. Cell Viability Test. Cytotoxicity of oxLDL was assessed
through MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
2H-tetrazolium bromide] conversion assay according to the
manufacturer’s instructions (Invitrogen, Milan, Italy). Cell
viability was expressed as percentage of the absorbance value
measured in control HUVEC.
2.7. Flow Cytometry Analysis. At the end of the incubation
time, HUVEC were washed with PBS, harvested with cell dis-
sociation medium, and diluted in a washing buffer contain-
ing PBS, 0.1% bovine serum albumin, and 1mM CaCl2.
Aliquots (0.1 to 0.5× 106 cells in 20μl) were seeded in a
96-well plate and incubated at 4°C with 2μg/well of a mouse
anti-human ICAM-1 or VCAM-1 or ELAM-1 or ABC-A1
monoclonal antibody FITC-conjugated (Invitrogen, Milan,
Italy). After 1 h at 4°C, cells were washed and analysed for
fluorescence on a flow cytometer (Epics II, Beckman Coulter,
US). At least 20000 events were analysed for each sample.
Data are expressed as median fluorescence intensity (MFI)
units, measured in the FL1 (green) channel with a 488 nm
(excitation) and 530nm (emission) filter set.
RONS concentration was evaluated by staining cells with
2′,7′–dichlorofluorescin diacetate dye (DCFDA) as reported
elsewhere [18].
2.8.QuantitativeReal-TimeReverse-TranscriptionPolymerase
Chain Reaction. Total RNA was isolated by employing an
RNeasy mini kit in accordance with the manufacturer’s
instructions (QIAGEN,Milan, Italy). RNA(5–10μg)was then
reverse-transcribed to cDNA using Superscript III Reverse
Transcriptase following themanufacturer’s protocol (Invitro-
gen, Milan, Italy) and stored at -20°C until tested. Real-time
PCR for ICAM-1, VCAM-1, ELAM-1, or ABC-A1 and
glucose-6-phosphate dehydrogenase (G6PDH) was carried
out with an RT Real-Time™ SYBR Green PCR Master Mix
and the RT2 PCR Primer Set in accordance with themanufac-
turer’s instructions (SuperArray, Milan, Italy) using an ABI
PRISM7700SequenceDetectionSystem(AppliedBiosystems,
Warrington, UK). The following primers were used in the
present study: human VCAM-1: (forward) 5′-CTTAAAATG
CCTGGGAAGATGGT-3′, (reverse) 5′-GTCAATGAGAC
GGAGTCACCAAT-3′; human ICAM-1: (forward) 5′
-GGCTGGAGCTGTTTGAGAAC-3′, (reverse) 5′-CTGA
CAAGTTGTGGGGGAGT-3′; human ELAM-1: (forward)
5′-GCCTGCAATGTGGTTGAGTG-3′, (reverse) 5′-ACGA
ACCCATTGGCTGGATT-3′; human ABC-A1: (forward) 5′
-TGTCCAGTCCAGTAATGGTTCTGT-3′, (reverse) 5′
-CGAGATATGGTCCGGATTGC-3′); and human GAPDH:
(forward) 5′-CCACATCGCTCAGACACCAT-3′, (reverse)
5′-CCAGGCGCCCAATACG-3. Thermal cycling conditions
included aprerunof 2min at 50°Cand15min at 95°C followed
by 40 cycles at 95°C for 30s, 55°C for 30s, and 72°C for 30s.
RT2-PCRdatawerequantifiedascycleof threshold (Ct)values,
and the relative expression of each gene was normalized to
housekeeping gene GAPDH.
2.9. Reporter Gene Assay. NF-κB activity was examined by
transfecting HUVEC with pNFκB-Luc luciferase construct
(Stratagene, CA, USA) as reported elsewhere [19]. Trans-
fected HUVEC were then cocultured with 100 μM oxLDL
in the absence or in the presence of indicaxanthin as detailed
above. After 6 h, cells were washed with PBS and lysed for
5min at 4°C using a lysis buffer according to the manufac-
turer’s instructions (Promega, WI, USA). Luciferase activity
is expressed as relative luminescence units (RLU)× 103 fol-
lowing reading in a TD/2020 luminometer (Turner Biosys-
tems, CA, USA).
2.10. Statistical Analysis. Data from all experiments are
reported as mean ± SD. Data were analysed and presented
using GraphPad Prism software (GraphPad). Comparisons
between two values were made using Student’s t-test, and
P < 0 001 were designated with triple asterisks. Multiple
comparisons were performed by one-way analysis of vari-
ance (ANOVA) followed by Tukey’s correction. Signifi-
cance was accepted when the null hypothesis was
rejected at the P < 0 001 level.
3. Results
3.1. Oxidative State Assessment of oxLDL. The oxidative state
of oxLDL was evaluated by assaying CD hydroperoxides and
TBARS levels. When compared to nLDL, treatment with
5 μM CuSO4 for 24 h determined a significant increase
(P < 0 001) of both CD and TBARS in the particle (Figure 2).
3.2. Effects of Indicaxanthin on the Viability of oxLDL-
Treated EC. Incubation of HUVEC with 100 μg oxLDL/ml
for 16 h determined a significant decrease (P < 0 001) of cell
viability as compared to control EC (Figure 3). On the other
hand, pretreatment of HUVEC with indicaxanthin at 5 μM
did not improve cell viability, while at 15 μM it caused a sig-
nificant (P < 0 001) inhibition of cell death that was
completely prevented with 20 μM indicaxanthin (Figure 3).
3.3. Effects of Indicaxanthin on oxLDL-Induced Protein and
mRNAUpregulation of AdhesionMolecules in EC. Incubation
of HUVEC with 100 μg oxLDL/ml for 16 h induced a signif-
icant (P < 0 001) increase of ICAM-1, VCAM-1, and ELAM-
1 regarding both protein and mRNA levels (Figures 4(a)–4(f
), respectively) in comparison with control cells. Noteworthy,
pretreatment of EC with indicaxanthin in a concentration
range between 5 and 20 μM caused a significant (P < 0 001)
concentration-dependent decrease of all the above-cited
adhesion molecules regarding both protein and mRNA levels
(Figures 4(a)–4(f), respectively). Importantly, incubation of
EC with 20 μM indicaxanthin in the absence of oxLDL did
not modify the adhesion molecule, regarding both protein
and mRNA levels, in comparison with control HUVEC.
3.4. Effects of Indicaxanthin on oxLDL-Induced
Downregulation of ABC-A1 in EC. Stimulation of EC with
100 μg oxLDL/ml induced a significant (P < 0 001) decrease
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of ABC-A1 regarding both protein andmRNA levels, in com-
parison with control HUVEC (Figures 5(a) and 5(b), respec-
tively). Noteworthy, pretreatment of EC with indicaxanthin
in a range between 5 and 20 μM caused a significant
(P < 0 001) concentration-dependent increase of ABC-A1
expression, regarding both protein and mRNA levels
(Figure 5). On the other hand, incubation of EC with 20 μM
indicaxanthin in the absence of oxLDL did not modify
ABC-A1atbothprotein andmRNAlevels, in comparisonwith
control HUVEC.
3.5. Effects of Indicaxanthin on oxLDL-Induced RONS
Production. In comparison with control HUVEC, stimula-
tion of EC with 100 μg oxLDL/ml induced a significant
increase of RONS levels (P < 0 001) (Figure 6). On the other
hand, pretreatment of EC with indicaxanthin in a concentra-
tion range between 5 and 20 μM caused a significant
(P < 0 001) concentration-dependent decrease of endocellu-
lar RONS production when compared to control EC
(Figure 6). Conversely, incubation of EC with 20 μM indicax-
anthin in the absence of oxLDL did not modify RONS levels,
in comparison with control HUVEC.
3.6. Effects of Indicaxanthin on oxLDL-Induced NF-κB
Transcriptional Activity. Stimulation of EC with 100 μg
oxLDL/ml induced a significant (P < 0 001) increase ofNF-κB
transcriptional activity, in comparison with control HUVEC
(Figure 7). Noteworthy, pretreatment of EC with indicax-
anthin in a concentration range between 5 and 20 μM caused
a significant (P < 0 001) concentration-dependent decrease
of the transcriptional activity (Figure 7). On the other hand,
incubation of EC with 20 μM indicaxanthin in the absence of
oxLDL did not modify the transcriptional activity of NF-κB,
in comparison with control HUVEC.
4. Discussion
The present investigation falls within the intense research on
the interplay between diet and immune function. The iden-
tity, the number, and the mechanisms of action of the protec-
tive agents we daily assume through our diet remain largely
unknown and require further research. However, before
defining appropriate clinical trials, it is crucial to evaluate,
through suitable in vitro assays, the health-promoting effects
of plant-derived compounds in order to identify the most
promising ones [1–3].
In line with this perspective, we investigated here the
protective effects exerted by indicaxanthin from cactus pear
fruits, at nutritionally relevant concentrations, in an in vitro
model of innate immunity activation represented by
oxLDL-induced endothelial dysfunction. Our findings dem-
onstrate that indicaxanthin protects EC from oxLDL-
induced damage in vitro, as evaluated by an increase of the
viability of EC pretreated with the phytochemical in the
range between 15 and 20 μM. ICAM-1, VCAM-1, and
ELAM-1 overexpression is a key event in the onset and the
development of EC dysfunction. Relevantly, it not only
increased indicaxanthin cell viability but also preserved cellu-
lar functions, counteracting the oxLDL-induced adhesion
molecule overexpression, from 5 to 20 μM. From a mecha-
nistic perspective, these effects were mediated by a modula-
tion of gene expression that led to a downregulation of
ICAM-1, VCAM-1, and ELAM-1 mRNA levels.
As stated above, many phytochemicals have shown
immunomodulatory effects, in vitro. However, a major limi-
tation for the employment of these compounds is their low
bioavailability. On the contrary, present results appear of
interest as indicaxanthin is effective at nutritionally relevant
concentrations, achievable in humans after the ingestion of
the fruit [14].
It is well established that endothelial adhesion molecule
expression is under control of several redox-regulated tran-
scription factors, including the master minder NF-κB [20].
Moreover, oxLDL have been demonstrated to activate vari-
ous transcription factors, NF-κB included. In line with this,
we demonstrated here an inhibition by indicaxanthin of the
transcriptional activity of NF-κB. This result appears consis-
tent with our previously reported findings on the NF-κB-de-
pendent immune-modulatory and anti-inflammatory effects
of indicaxanthin both in vivo and in vitro. Relevantly, the
inhibition of the NF-κB transcriptional activity appears to
be strictly consistent with the ability of indicaxanthin to
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Figure 2: Amount of CD hydroperoxides and TBARS in the oxLDL
employed in the study in comparison with untreated ones (nLDL).
Values are the mean ± SD of three separate experiments carried
out in duplicate; ∗∗∗P < 0 001.
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inhibit oxLDL-induced endocellular oxidative and nitrosa-
tive stress. Along these lines, we therefore propone that the
phytochemical counteracted the oxLDL-induced adhesion
molecule overexpression by inhibiting NF-κB transcriptional
activity, through a redox-dependent mechanism.
Along with ICAM-1, VCAM-1, and ELAM-1 overex-
pression, disruption of the reverse cholesterol transfer across
the endothelium, via ABC-A1 downregulation, represents
another key aspect of EC dysfunction and cholesterol deposi-
tion within the arterial wall. It is well known that oxLDL
decreases ABC-A1 levels in EC via inhibiting liver receptor
X (LXR) [4]. We found here that indicaxanthin counteracted
the oxLDL-induced ABC-A1 downregulation. The observed
inhibitory effects of indicaxanthin of the transcriptional
activity of NF-κB can also be connected with its ability to
counteract the oxLDL-induced ABC-A1 downregulation.
Indeed, several lines of evidence show that ABC-A1 can be
upregulated, rather than through the activation of the LXR
pathway, via the inhibition of the redox-sensitive ERK/NF-
κB pathway [21–25].
Finally, notwithstanding that indicaxanthin at 5 μM does
not improve EC viability, it does, however, significantly
reduce adhesion molecule overexpression, NF-κB transcrip-
tional activity, and RONS production and increases ABCA-
1 expression.
5. Conclusions
Evaluating the activities of healthy, plant-derived com-
pounds to select the most promising ones through suitable
in vitro assays is imperative before defining appropriate clin-
ical trials. We demonstrated here that indicaxanthin, a
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Figure 4: ICAM-1, VCAM-1, and ELAM-1 protein (a–c) and mRNA (d–f) levels of HUVEC stimulated with oxLDL, either in the absence or
in the presence of indicaxanthin at different concentrations for 16 h. Values are themean ± SEM of three separate experiments carried out in
triplicate. Labeled means without a common letter differ; P < 0 001.
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bioavailable, redox-modulating phytochemical with anti-
inflammatory activity, is able to exert remarkable protective
effects in an in vitromodel of vascular inflammation, at nutri-
tionally relevant concentrations. In light of its ability to
modulate specific endothelial genes involved in leukocyte
adhesion and cholesterol transport, through a redox-depen-
dent, NF-κB-mediated mechanism, indicaxanthin might be
further investigated in vivo as a potential endothelial-
protective agent of dietary origin.
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